21 results
8-K
EX-99.1
VYNT
Vyant Bio, Inc.
16 Nov 22
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
5:26pm
, 2022 we submitted a clinical trial application with the Alfred Hospital Human Research Ethics Committee (HREC) to conduct a phase 2 proof-of-concept
8-K
EX-2.1
VYNT
Vyant Bio, Inc.
3 Nov 22
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
9:10am
jurisdiction; (v) the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7(b)), the federal Ethics in Patient Referrals or the “Stark Law” (42 U.S.C. § 1395nn … , and only as approved by applicable institutional review boards or ethics committees.
(d) For the past five (5) years, the Company has not: (a) billed nor
424B3
dsidjatxow7v5
12 Feb 21
Prospectus supplement
9:43pm
S-4/A
0je8fw5r7g3f6cnxqkr
8 Feb 21
Registration of securities issued in business combination transactions (amended)
10:46am
S-4
hnblw
16 Oct 20
Registration of securities issued in business combination transactions
11:38am
PRE 14A
if95vi2kvk xmsa
19 Apr 19
Preliminary proxy
4:47pm
425
EX-10.1
x7w4n ib8y
21 Nov 18
Business combination disclosure
4:13pm
8-K/A
EX-10.1
n5cl toezet0zmtel6q
21 Nov 18
Departure of Directors or Certain Officers
4:10pm
10-K/A
hmlbnpd55bwzjfxq9gel
28 Apr 16
Annual report (amended)
12:00am